Please login to the form below

Not currently logged in
Email:
Password:

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

Maura Dickler is set to join Lilly Oncology as VP of late phase development on May 7.

She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine Service within its Department of Medicine.

In her new role at Lilly Oncology she will report to senior vice president, global development and medical affairs Levi Garraway.

He said: "Dr Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities. Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly."

In addition to her role at Sloan Kettering, Dr Dickler concurrently serves as associate professor of medicine at New York’s Weill Cornell Medical College.

15th March 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...

Infographics